Journal of Emerging Trends in Engineering and Applied Sciences (JETEAS) 4(2): 242-249 Scholarlink Research Institute Journals, 2013 (ISSN: 2141-7016) Jjo
g Engineering and Applied Sciences (JETEAS) 4(2):242-249 (ISSN: 2141-7016)
Quality Control of Drugs: A Case of Erythromycin Tablets in Chemist Shops of Meru Town. Kenya 1Dr. Kei Robert M. and 2Dr. Mutuma Kenneth
1School of Public Health , Moi University. Kenya.
Corresponding Author: Kei Robert M. __________________________________________________________________________________________ Abstract Erythromycin stearate has been used for long in treatment of infections caused by susceptible strains of the designated organisms in many diseases. Because of this widespread use of the drug, there is an equally increased demand for cheaper generic erythromycin stearate tablets, of which their potency remains uncertain and hence compromise health. Therefore, there is need to determine quality of drugs sold to the public. Chemist shops selling human medicine in Meru Town. Fifty (50) chemist shops selling human medicine in Meru Town. The objective is to analyze erythromycin tablets for their quality performance by determining their potency through microbiological assay, disintegration time test and friability test. This was analytical study design. The samples of erythromycin tablets from selected manufacturers were bought from sampled chemists in Meru Town and analysed in the laboratory in order to determine their quality. All the samples examined passed the disintegration time test; friability test except microbiological assay. Perhaps, this may be due to faulty quality assurance and control during the process of manufacture and storage. There is need for sustained market surveillance of erythromycin tablets to ensure quality standards are maintained. Also further research should be done in order to establish the quality of other drugs in the market. __________________________________________________________________________________________ Keywords: quality control; microbiological assay: disintegration time test; friability test. INTRODUCTION
market is efficacious, safe and of good quality.
The supply of good quality essential drugs was
(Editorial Afr J pharm2003). Thus most countries
recommended in the Alma-Ata declaration of 1978 as
require that drugs must be evaluated and registered
one of the prerequisites for the delivery of health
before they are allowed to be freely sold within their
care. When the concept of Essential Drugs List
jurisdiction.(Thoithi 2003). In some countries drug
(EDL) was introduced by World Health Organization
registration exercises are complemented by a Drug
(WHO) some governments embraced it, Kenya
Quality Control Laboratory which monitors quality of
included. They developed EDLs on which they based
products on the market. In some cases the laboratory
their procurements in terms of maximum quantity at
carries out an analysis in order to finalize an
minimum cost. The drugs procured from both local
and international suppliers are assumed to be of good
quality. This however, seems to have resulted in
A new product so termed “the innovator brand” sets
“cheap” drugs which in some occasions are of
the bench mark on quality of the drug molecule. The
pharmaceutical development of a dosage form and
use of the same in clinical trials will establish quality
The WHO Certification Scheme on the quality of
parameters such as, quantity of active ingredient,
pharmaceutical products moving in international
allowable levels of degradation products and related
commerce has not achieved the desired results. The
substances and dissolution disintegration tests
reasons for this are many and varied. They
amongst others. Other quality indicating parameters
nevertheless revolve around the tenets of WHO
must conform to compendia requirements for the type
procurements which usually assume that an adopting
of dosage form.(Renington 1990). Any generic
or implementing country has the will and
formulations that may be developed later on must of
implementing mechanisms to achieve the objectives.
necessity be equivalent to the innovator product in
Nevertheless, a quality drug is the most critical
terms of quality. The quality of generics is an area
armamentarium in the treatment or management of
that requires critical scrutiny during the vetting of
some disease states. Drug registration constitutes the
documents. While the drug molecule is well known
first line activity in ensuring that a product on the
in terms of safety and efficacy, pharmaceutical
Journal of Emerging Trends in Engineering and Applied Sciences (JETEAS) 4(2):242-249 (ISSN: 2141-7016)
formulations cannot be the same. In Kenya, samples
The data generated by previous researchers goes to
of products are sent to the National Quality Control
emphasize that there are both good quality and poor
Laboratory (NQCL) for evaluation of quality before
quality products in Kenya (Chitneni et.al 2004). The
magnitude of poor quality products remains to be
determined. This would require well thought out
Quality Assurance (QA) in the pharmacy context
market surveillance programmes by NQCL, Drug
refers to the total sum of all those processes that are
Analysis and Research Unit (DARU) and any other
necessary to ensure the drug product is of good
similar laboratories. Such programmes should be
quality, effective and safe up to the point it is
funded by the Pharmacy and Poisons Board as one of
administered to the patient within its stated shelf life.
their objectives in ensuring quality drugs in the
It involves several aspects which broadly fall into
four categories. The first aspect of QA involves
registration of the drug product prior to marketing in
Situation in Kenya
the recipient country. A dossier containing all
In Kenya, the National Quality Control Laboratory
relevant information on the product is submitted and
(NQCL) is the quality control arm of the Pharmacy
evaluated by a committee of experts representing
and Poisons Board established under the Pharmacy
different specialties. Information sought includes
and Poisons Act, Cap 244. The objective of the
evidence of quality, safety and efficacy. QA measures
NQCL is to ensure that the quality of drugs available
must meet internationally accepted standards as
on the Kenyan market are safe, efficacious and of
high quality. This is achieved by appropriate testing
Pharmacopoeia, British Pharmacopoeia, and US
of drugs before the Pharmacy and Poisons Board
recommended shelf life must be submitted. Other
information includes evidence of registration in
Over the past years, Kenya has been treated to press
country of origin and other countries where quality
reports about poor quality pharmaceuticals in the
market and problems with the same in public
institutions (Leal 2001). This therefore, raises
The second aspect of QA is evidence of Good
concern about the quality of generic drugs in the
Manufacturing Practice (GMP), which must focus on
market. Defects in the regulatory procedures have
the standard of raw material, the manufacturing
made it attractive for some traders to introduce
facility, the in-house production and control
substandard generic medicines in the market. The
measures, packaging, storage, quality control of
Generic drugs are as safe as their branded
finished product, qualifications and competence of
counterparts only if the later have passed the quality
personnel. In earlier years emphasis had been on
control and safety tests. However, there still remains
analysis of finished product, but later in the 1970’s
a question on the quality of these drugs.
During manufacture of antibiotics, the drug content
The third aspect of QA is the control of the finished
and physical characteristics are closely monitored to
product. Although the manufacturer of a drug product
avoid incidences of producing substandard products.
is expected to carry out analysis of the product as part
of GMP, it is necessary for such results to be
validated by an independent and reputable laboratory.
This is done through in-process quality control and
Tests include confirmation of label specifications,
quality control of finished products. However,
dissolution rates, and limit tests for contaminants and
incidences of antibiotics having less drug content
degradation products. For a generic product, the
than the claimed content are common. The products
innovator product serves as point of reference. For
especially tablets may also have poor disintegration
antibiotics, chemical assay serves a limited purpose
and the antimicrobial assay is preferable. For generic
Previous work shows that there are both good quality
and poor quality products in Kenya. The magnitude
of poor quality products remains to be determined.
The fourth aspect of QA is pharmacosurveillance
This would require well thought out market
(post marketing surveillance) of drug products.
surveillance programmes by NQCL, DARU and any
Despite all the precautionally measures taken to
ensure safe and effective product, there are some
Previous market surveillance studies have been done
on many products on the Kenyan market. A previous
negatively as the product moves along the supply line
study on quality of amoxycillin preparations on the
from the manufacturer, wholesaler, retailer/hospital,
Kenyan market indicates that following the
and eventually the patient (Editorial Afr J.pharm
evaluation of the content of some 33 amoxycillin
capsule formulations, all the failed products were
Journal of Emerging Trends in Engineering and Applied Sciences (JETEAS) 4(2):242-249 (ISSN: 2141-7016)
manufactured locally. (Kamau et.al 2003). In the
the Kenyan market and that erythromycin is also
same study, the evaluation of the amoxicillin content
listed in the Essential Drug List, so far there is no
in oral suspensions indicates that the content of
study on erythromycin as to matters of quality.
amoxicillin in all the products changed within the
Therefore, this study is directed at ascertaining the
seven days under the storage conditions. Study done
quality of some of the erythromycin products on the
on quality control of antiretroviral drugs analyzed in
the Drug Analysis and Reasearch Unit during 2000-
2003, indicates that a total of 33 drugs samples were
Erythromycin
analyzed of which 31 (93.9%) were generic products
Erythromycin, produced by Saccharopolyspora
and only 2 were innovator products (Obuga et.al
2003). This reflects the current government policy to
erythraeus) is a complex macrolide antibiotic
encourage marketing of generic ARVs, which are far
consisting of erythromycin A, a 14 membered lactone
much affordable than the brands. The analysis results
ring with a 9-keto group, carrying a neutral and
obtained showed that 30 of the samples complied
amino sugar (Labenda 1987). It has two glycosidic
with the USP specifications while 3 generic products
bonds and a basic dimethylamino group on
desosamine. The biosynthesis of erythromycin can be
divided into two phases. In the first phase the
Surveys have also been done on quality of
polyketide synthase (PKS) catalyzes sequential
sulphadoxine/pyrimethamine tablet products on the
condensation of one unit of propionyl CoA and six
Kenyan market (Kibwage et.al 2000). This involved
the evaluation of parameters of the tablets that are
likely to affect their bioavailability, that is, the
content of active ingredients (APIs) and dissolution.
deoxyerythronolide B is elaborated by a series of
In the study 26 batches were analyzed of which the
"tailoring" enzymes which include regiospecific
content of APIs for all the examined batches were
hydroxylases, glycosyl transferases, and methyl
within the USP limits of the label amount except for
transferases. From the biosynthetic point of view
one batch which was below the limits. On the
most interest is focused on the operations of the PKS
dissolution test only 30% of the analyzed samples
in phase 1, but the late steps are essential to produce
passed the test. A study done on the quality of
active antibiotics. Semi-synthetic derivatives of
ampicillin preparations on the Kenyan market
Erythromycin have been directed at producing
indicate that upon evaluation of the chemical content
compounds with increased potency and increased
of 20 ampicillin capsules and 2 tablet products, four
stability in acidic and basic environments. These
capsule products failed to comply with the
include roxithromycin, azithromycin, flurithromycin
pharmacopoeal label claim (Kamau et.al 2001). In the
same evaluation the content of ampicillin in oral
suspensions for five products failed the test. Analysis
Erythromycin Indications
of co-trimoxazole products on the Kenyan market has
Erythromycin stearate has been used for long in
also been done whereby in the study there were a
treatment of infections caused by susceptible strains
total of 9 samples from 7 local products of which 2
of the designated organisms in many diseases which
failed the content. Of the 9 imported products, 13
includes respiratory tract infections especially upper
samples were analyzed and 4 failed the content
respiratory tract infections of mild to moderate
specifications. Six samples failed the specifications
pyogenes,
for content of active ingredients.(Kibwage et.al
Streptococcus pneumoniae, or Haemophilus and
1998). An observation on drug quality control in
lower-respiratory tract infections of mild to moderate
Kenya by the Drug analysis and Research Unit
severity caused by Streptococcus pneumoniae or
indicates that the failure rate of drugs analyzed in
Streptococcus pyogenes. It is also used in respiratory
DARU over the period 1996-2000 is higher (23.6%)
tract infections due to Mycoplasma pneumoniae and
compared to those analyzed in the same laboratory in
skin and skin structure infections of mild to moderate
the period 1991-1995 (17.5%) (Thoithi 2002). There
severity caused by Streptococcus pyogenes or
is therefore need for manufacturers to pay attention to
such batch to batch variations that may arise and
identify causes of them. The use of poor quality
In addition, it is indicated in pertussis (whooping
products especially antibiotics can have serious
cough) caused by Bordetella pertussis. Erythromycin
consequences including development of drug
is effective in eliminating the organism from the
resistance and therapeutic failure. The results of these
nasopharynx of infected individuals rendering them
studies support the continuing need for quality
noninfectious. In infections due to Corynebacterium
certification before and market surveillance after
diphtheriae, it is used as an adjunct to antitoxin to
products are released into the market by reputable
prevent establishment of carriers and to eradicate the
laboratories as more products enter the Kenyan
organism in carriers. Erythromycin is also used in
market. Despite the many studies on drug products on
intestinal amebiasis caused by Entamoeba histolytica,
Journal of Emerging Trends in Engineering and Applied Sciences (JETEAS) 4(2):242-249 (ISSN: 2141-7016)
acute pelvic inflammatory disease caused by
variation of responses, replication of treatment is
Neisseria gonorrhoeae and treatment of infections
necessary (William et.al; 2001). Microbiological
assay has an advantage over physical and chemical
tetracyclines are contraindicated or not tolerated,
methods of assay in that it directly detect biological
erythromycin is indicated for the treatment of
activity and measure potencies of antibiotics hence
nongonococcal urethritis caused by Ureaplasma
are preferred in the analyses of antibiotics. In case of
urealyticum. Moreover, it is indicated in primary
related substances which show activity, this method
cannot be used. It is time consuming and labor
Erythromycin (oral forms only) is an alternative
choice of treatment for primary syphilis in patients
allergic to the penicillins. It is also used in
Disintegration Time Test
Disintegration is defined as that state in which no
pneumophila and prophylaxis in prevention of initial
residue of the tablets and capsules, except fragments
of undissolved coating, remains in the test solution.
Erythromycin has been used for treatment of several
The method provides a rough estimate of the time
infection diseases and in patients allergic to the
limit (30 minutes) required for all uncoated tablets
effervescent, and film-coated tablets, that is, all quick
Microbiological Assay
release formulations of a drug dosage form to
This is a technique whereby the potency or the
disintegrate in water at 37± 2°C. If a drug product
concentration of a chemical substance may be
does not pass this test, there is a major defect in its
determined by its effect on the growth of a
quality because it will not dissolve, absorb and
microorganism either by promoting the growth or by
become bioavailable. The product can be rejected at
inhibiting the growth. The potency of a sample of an
this stage with no further investigation (Renington
antibiotic is determined by comparing the dose that
inhibits the growth of a suitable susceptible
microorganism with the dose of the standard
Friability Test
preparation of that antibiotic that produces similar
This is one of the criteria for testing mechanical
inhibition. Biological methods directly detect
strength of tablets. During the process of coating and
biological activity and measure potencies of
transportation, the tablet will lose some weight. To
antibiotics hence are preferred in the analyses of
measure the weight loss the samples are counted and
antibiotics. The procedures employed in microbial
weighed. Thereafter, the friability test is performed
assay of antibiotics may be broadly divided into two.
following the individual monographs of the relevant
The first is the turbidimetric method where the extent
pharmacopoeia. When finished, the samples have to
of growth of an organism in a liquid nutrient medium
be de-dusted and weighed again. The difference
is dependent on the quantity of the active substance
between the weight before and after the test is
added to and mixed uniformly with the liquid
determined as friability, which should not usually
medium. Growth of the microorganism is measured
LIMITATIONS OF THE STUDY
The second is the cylinder plate method in which an
Tablet Hardness Test was not done because there
aqueous solution is placed in contact with a solid agar
were no B.P. Specifications for film coated
gel on a plate. The solute diffuses from the solution
erythromycin tablets. Again, due to financial
into the gel until equilibrium is set. The agar contains
constraints the study could not cover other drugs in
nutrients to support the growth of the microorganism
and is inoculated with a suspension of the test
organism. The organism grows and multiplies until it
MATERIALS AND METHODS
is inhibited by the antibiotic, yielding a clear zone of
The study was carried out in Meru Town of Meru
inhibition. The zone is as a result of the outward
County, Kenya. This was to determine the quality of
diffusion of the antibiotic from a reservoir into a
generic erythromycin tablets sold in the chemist
layer of the inoculated medium to yield a circular
shops selling human medicine. The study was guided
zone of inhibition. The critical concentration of the
by analytical study design, through, performing
antibiotic, the period of growth of the organism and
microbiological assay, disintegration test and
the population of the microorganisms affects the zone
After listing the chemists (50), erythromycin tablets
The test solutions are made as dilutions in a series of
(20) were purchased from randomly sampled
two ore more concentrations prepared from reference
chemists (20) and taken to the laboratory for analysis,
standard and the unknown samples for application on
the test system. To minimize the effect of random
Journal of Emerging Trends in Engineering and Applied Sciences (JETEAS) 4(2):242-249 (ISSN: 2141-7016)
To ascertain the quality of generic Erythromycin
Namur, Belgium) used for ensuring complete
tablets collected, the following tests were carried
dissolution of solutes. MEMMERT incubator Range
out:- disintegration time test, friability test and
BE (analis, Namur, Belgium) used for incubating the
microorganism cultures. AC600 Series vertical
laminar flow workstation (Vermeulen I.j, Germany)
used for carrying out the microbiological procedures.
Brand name Manufacturer Supplier
Mettler Toledo PB3002 Data Range weighing
balance (Switzerland) used for weighing reagents and
media. Dixons ST19 Aluminium portable autoclave
(UK) used for sterilizing the media. MEMMERT
Universal Oven and Sterilizer Model U (Analis sa,
Belgium) used for drying and sterilizing glassware.
LMS Laboratory refrigerator used for storing culture
plates and microorganisms. An electronic digital
caliper used for measuring the zone of inhibition.
Disintegration Time Test
One tablet or capsule was placed into a 100-150 mL
wide neck bottle containing 100 mL water at close to
37± 2°C. The liquid was then stirred by swirling the
bottle periodically. The time (in minutes) when
EQUIPMENT AND APPARATUS
disintegration is complete was read and recorded. The
Sartorius CP225D Balance (Elisters 2000 Ltd.,
test was repeated on five additional tablets.
Namur, Belgium) used for weighing accurately the
samples. Friabilator model PTF1 (Pharmatest GmbH,
The batch passes disintegration time test if all six
Germany) used for carrying out the friability test.
tablets disintegrate within 30 minutes. Should one
Disintegration tester PTZ1 (Pharmatest GmbH,
tablet fail to disintegrate, the entire test cycle was to
Hainburg, Germany) used for carrying out the
be repeated. The batch fails disintegration test if one
disintegration time test. Schleuniger-2E, tablet
of the additional tablets fail again in the second run.
hardness tester used for carrying out the tablet
hardness test. BRANSON 2200 stirrer (analis,
Table 11: Disintegration Time Test Time in Minutes Erocos 250 Erocos 500 Rythro 500 BN: 062202 BN: 062117 BN: 6F250 BN: RE6001 Friability test
friabilator. The results obtained are shown in table
The test was carried out as per the B.P 2007
VOLUME 1V APPENDIX XVII G method using a
Table 111: Friability Test Parameter /tablet Erocos 250 Erocos 500 Rythro 500 BN: 062202 BN: 062117 BN: 6F250 BN: RE6001
Journal of Emerging Trends in Engineering and Applied Sciences (JETEAS) 4(2):242-249 (ISSN: 2141-7016)
Microbiological assay
hours. The diameters of the zones of inhibition
Diffusion Assay Method A BP (2005)
produced by various concentrations of the Standard
Tryptone Soya Agar (4.0g) was suspended in 100.0
Preparation and the substance being examined were
mL of distilled water and brought to boiling to
then measured using the zone reader (British pharm
dissolve completely. This was then sterilized by
2005). The potency was then calculated according to
autoclave at 121˚C for 15 minutes. A solution of
phosphate buffer of pH 8.0 was prepared by mixing
Formula 1:
orthophosphate with 46.80 ml of 0.2M NaOH VS and
diluted to 200.0 mL with water. A concentration of
30 mg/50 mL of the standard in distilled methanol
was prepared by weighing 31.05 mg of erythromycin
A base 96.6% and dissolving in methanol in a 50.0
% LC = Weight of Standard x Antilog m x Purity x 100
The test sample was prepared by weighing and
powdering 20 tablets. A quantity of the powder
corresponding to the most concentrated to the least
containing the equivalent of 30 mg of Erythromycin
concentrated of the standard samples respectively and
was dissolved as completely as possible in sufficient
T3, T2 and T1 are zone diameters corresponding to
methanol to produce 50.0 mL and the biological
the most concentrated to the least concentrated of the
assay of antibiotics for erythromycin carried out. Dilution of the sample and standard solutions was
carried out as follows. From the original solution, 5.0
Table 1V: Potency of the products analyzed
mL of the solution was transferred to a 25.0 mL
volumetric flask and made up to the mark with the
% label claim
phosphate buffer. 10.0 mL was further diluted to 25.0
mL with the phosphate buffer. Finally, 10.0 mL of
this solution was transferred to a third 25.0 mL
volumetric flask and made up to the mark with the
phosphate buffer. The volumetric flasks were labeled
DISCUSSION
Petri dishes were filled to a depth of 3 to 4 mm with a
According to the B.P. (2005) specifications for
tryptone soy agar medium that has previously been
uncoated tablets the tablets disintegrate within 15
inoculated with 1% w/v of a suitable inoculum of
minutes unless otherwise justified and authorized. If
Bacillus pumilis. When the inoculum consisted of a
the preparation fails to comply because of adherence
suspension of vegetative organisms, the temperature
of the tabs to the discs, a repeat of the test on a
of the molten agar medium was not exceed 48˚C to
further 6 tablets omitting the disc is required. The
50˚C when it was inoculated was kept at a
preparation being examined complies with the test if
temperature of 37˚C. The dishes were specially
all 6 tablets have disintegrated. Rythro 500 (BN
selected with flat bottoms and placed on a level
RE6001) is an uncoated erythromycin tablets. The
surface so as to ensure the layer of the medium will
disintegration time test for the six tablets was about
be of a uniform thickness. The inoculated plates were
one minute. All the tablets disintegrated within this
allowed to dry for 30 minutes at room temperature
time. The tablets therefore, comply with the B.P
disintegration test for tablets and capsules. In case of
coated tablets, unless otherwise justified and
Wells 5 to 8 mm in diameter were bored in the
authorized, film coated tablets disintegrate within 30
medium with a sterile borer. Solutions of the standard
minutes and other coated tablets disintegrate within
preparation of known concentration and solutions of
60 minutes. The preparation being examined
the substance being examined were prepared in a
complies with the test if all 6 tablets have
sterile phosphate buffer of a suitable pH value. The
disintegrated in the medium. Erocos 250 (BN
solutions were then introduced to the wells by means
062202), Erocos 500 (BN 062117), Elocin (BN
of a pipette. Three different doses of the standard
6F250) and Elocin (BN 7C55) were film coated
preparation and of the sample being examined having
erythromycin tablets. The four batches comply with
the same presumed activity as the solutions of the
the B.P. disintegration test for tablets and capsules.
standard were used in order to be able to assess the
validity of the assay. The plates were maintained at
In reference to the B.P. (2007) specifications,
room temperature for 2 hours, during which time
generally the friability test is run once. If obviously
diffusion of the antibiotic into the medium occurs
cracked, cleaved or broken tablets are present in the
then incubated at suitable 37˚C for approximately 18
tablet sample after tumbling, the sample fails the test.
Journal of Emerging Trends in Engineering and Applied Sciences (JETEAS) 4(2):242-249 (ISSN: 2141-7016)
A maximum loss of mass (obtained from a single test
2. That further research should be done in
or from the mean of 3 tests) not greater than 1% is
order to establish the quality of other drugs
considered acceptable for most products. All the
samples passed the friability test as per the B.P.
REFERENCES
Abuga,K.O,. Mwagiru P.M., Thoithi G.N. Nguyo
The B.P. (2005) limits of biological assay for
J.M.,. Ngugi J.K, King’ondu O.K., Mugo H.M. and
erythromycin specifies that the precision of the assay
Kibwage. I.O. 6 (2003) No. 1. Quality control of
is such that the fiducial limit of error is not less than
antiretroviral drugs analyzed in the Drug Analysis
95% and not more than 105% of the estimated
and Research Unit during 2000-2003. East Cent. Afr.
potency. Rythro 500 (BN RE6001), Erocos 500 (BN
062117), and Elocin (BN 6F250) comply with the
B.P specifications for the fiducial limit of error.
British Pharmacopoeia, HMS, London, U.K. 2005.
However, two products, Erocos 250 (BN 062202)
and Elocin (BN 7C55), failed the test because they
British Pharmacopoeia, HMS, London, U.K. 2007.
had a higher value than the stated percentage label
claim. These did not comply with the B.P
specifications for the fiducial limit of error of not less
Chitneni S.K., Govaerts C., Adams E., Schepdael
than 95% and not more than 105% of the estimated
A.V. and Hoogmartens J. (2004). Identification of
potency. Products with higher quantity than the
specified amount of the drug can result in increased
chromatography-mass spectrometric detection. J.
levels of toxic effects of the drug. On the other hand,
low quantity of the drug will lead to pharmacological
ineffectiveness and promote the development of drug
Dehouck, P., Van Looy, E., Haghedooren, E.,
Deckers, K., Vander Heyden, Y., Adams, E., Roets,
E. and Hoogmartens, J. (2003). Analysis of
There are many generic erythromycin tablets in the
erythromycin and benzolperoxide in topical gels by
Kenyan Market, the quality of which remains
liquid chromatography. J. Chromatogr. B 794: 293-
uncertain. There is therefore, the need for critical
control of the quality of generic erythromycin tablets
in the Kenyan Market. The quality specification for
Editorial. 6(2003) No. 3. Quality Assurance of
the active and non-active ingredients should be of
Pharmaceutical Products. East Cent. Afr. J. Pharm.
interest to manufacturers and the drug regulatory
authorities. The performance of the dosage form
during a claimed shelf life in comparison to the
innovator product should be routinely assessed. This
Determination of selected human pharmaceutical
will help in the prevention of development of
compounds in effluent and surface water samples by
The results obtained show that two products of the
tablets analyzed do not comply with the B.P
specifications for the estimated potency
Kamau F.N, Thoithi G.N. and Kibwage. I.O.
4(2001) No. 1. Quality of Ampicillin preparations on
CONCLUSION
the Kenyan market. East Cent. Afr. J. Pharm. Sci.
The objective of the study was to analyse the sampled
erythromycin tablets in order to determine their
quality. The samples analysed passed disintegration
Kamau F.N, Thoithi G.N., Ngugi J.K. King’ondu
time test and friability test except microbiological
O.K and . Kibwage. I.O 6(2003) No.3. Quality of
assay. This may be due to faulty quality assurance
Amoxycillin preparations on the Kenyan market. East
and control during the process of manufacture or
inadequate storage conditions in the supply chain.
RECOMMENDATIONS
Pharmaceuticals in Kenya - an overview. East Cent.
The following recommendations were drawn from
Kibwage I.O., Olive O, Isaiah G. Mureithi, J.K.
surveillance of erythromycin drugs to ensure
Thuranira, J. 1(1998) No. 2. Hoogmartens. Analysis
of Co-trimoxazole products on the Kenyan market. East Cent. Afr. J. Pharm. Sci. 34 – 38.
Journal of Emerging Trends in Engineering and Applied Sciences (JETEAS) 4(2):242-249 (ISSN: 2141-7016)
Kibwage I.O. and Nguyo. J.M. 3 (2000) No. 1. Quality
products on the Kenyan market. East Cent. Afr. J. Pharm. Sci. 14 – 19. Koch, W. L. (1979). Erythromycin. In “Analytical Profiles of Drug Substances”. Vol. 8. pp. 159-177. Labeda D.P. (1987). Transfer of the type strain of Streptomyces erythraeus (Waksman 1923) Waksman and Henrici 1984 to the genus Saccharopolyspora Lacey and Goodfellow 1975 as Saccharopolyspora erythraea sp. nov., and designation of a neotype strain for Streptomyces erythraeus. Int. J. syst. Bacteriol. 37: 19-22. Leal, C., Codony, R., Compano, R., Granados, M. and Dolars Part, M. (2001). Determination of macrolide antibiotics by liquid chromatography. J. Chromatogr. A 910: 285-290. Omura, S. (ed) (1984). Macrolide Antibiotics: Chemistry, Biology and Practice. p.26. O’Neil M.J., Smith A., Heckelman, P.E. and Budavari S. (2001). The Merck Index – An Encyclopedia of Chemicals, Drugs and Bilogicals. 13th ed. pp. 654655 Merck & Co., Inc. Whitehouse Station
Ray W.A., Murray K.T., Meredith S., Narasimhulu S.S., Hall K., Stein C.M. ( 2004) Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes. N. Engl. J. Med 2004; 351:1089-96, and British National Formulary "BNF 49" March 2005. Remington’s Pharmaceutical Sciences. 18th ed. (1990). p.1639. Thoithi G.N, Abuga K.O ,. Nguyo J.M, Mukindia G., King’ondu O.K, Ngugi J.K and Kibwage. I.O. 5(2002) No. 2. Drug Quality Control in Kenya. Observation in in the Drug Analysis and Research Unit during the period 1996-2000. East Cent. Afr. J. Pharm. Sci. 28-32. William H.,and Stephen V.,(2001). Theory and application of microbiological assay. Page 1-3, 39-41 and 74-75.
PRESCRIPTION DRUG RIDER This Prescription Drug Rider (“Rider”) is made a part of Coventry Health and Life Insurance Company’s Certificate of Coverage (“COC”). The benefits provided by this Rider become effective on the date Coverage under the COC is effective. PRESCRIPTION DRUG BENEFITS Subject to the terms, conditions and scope of coverage, including all Exclusions, Limitati
FEDERAL CIRCUIT DECISIONS FOR WEEK ENDING December 13, 2013 Galderma Laboratories, L.P., v. Tolmar, Inc., (December 11, 2013) (precedential) Patent Nos. 7,579,377; 7,737,181; 7,834,060; 7,838.558; and 7,868,044. Key point(s): • Claims to a compound known to have a property at a specific concentration can be shown to be obvious by introducing prior art that teaches the usefu